KLRC1 and cancer: In this study, we initially developed a tri-specific Nano-Antibody (Tri-NAb) that targets PDL1/4-1BB/NKG2A to simultaneously activate NK and CD8+ T cells, thereby harnessing the innate and adaptive immune systems of the host for effective cancer eradication.